GHRP-2
Also known as: Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
Overview
GHRP-2 is a synthetic hexapeptide derived from met-enkephalin structure that functions as a potent GHS-R1a agonist. It is one of the most potent GHRPs in terms of GH release amplitude, capable of stimulating pulsatile GH secretion by over threefold compared to GHRH alone. GHRP-2 is approved in some countries for diagnostic testing of GH secretory capacity (as pralmorelin). It stimulates both GH and to a lesser extent ACTH and cortisol, making it less selective than ipamorelin.
Mechanism of Action
GHRP-2 activates GHS-R1a receptors with high affinity, triggering intracellular calcium signaling and protein kinase C activation in pituitary somatotrophs. This drives GH gene transcription and pulsatile GH secretion. Studies show it may stimulate anterior pituitary GH production up to 181 times baseline, with IGF-1 levels rising from ~100 to ~180 mcg/L. It also stimulates ghrelin release, appetite, and modest ACTH/cortisol elevation.
Potential Benefits
- Among the most potent GH-releasing peptides by amplitude
- IGF-1 elevation supporting muscle growth and recovery
- Pulsatile GH secretion mimicking physiological patterns
- Used as a diagnostic agent for GH deficiency evaluation
- Potential muscle hypertrophy and anti-atrophy effects
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 100-300 mcg/dose, 2-3x/day |
| Beginner | 100 mcg once daily at bedtime |
| Intermediate | 200 mcg twice daily |
| Advanced | 300 mcg 2-3x/day (morning, pre-workout, bedtime) |
| Cycle Duration | 6-8 weeks |
| Cycle Off | 4 weeks (to prevent tachyphylaxis) |
GHRP-2 is more potent than GHRP-6 but also stimulates cortisol and ACTH. Fasted state required for maximal GH response. Doses above 300 mcg do not increase GH output proportionally.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — rapid pituitary GH release
Standard method. Typical dose 100–300 mcg, 2–3x daily on empty stomach. Peak GH at 15–30 minutes post-injection.
Intranasal Lower than injection — ~20–30% relative
Convenience route. Requires higher doses to achieve comparable GH release. Less reliable absorption.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving GHRP-2:
GH Maximization Stack
Maximum GH release pairing. GHRP-2 is the most potent GHRP — combined with CJC-1295's GHRH amplification, this produces significant GH/IGF-1 elevation. 100–300 mcg each, 2–3x daily on empty stomach.
Anti-Aging GH Stack
GH optimization with longevity support. GHRP-2/CJC-1295 for GH secretion, Epitalon for telomere maintenance and melatonin restoration.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 5mg, 10mg |
|---|---|
| BAC Water | 2ml per 5mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Shelf Life | 28 days refrigerated |
Need exact syringe measurements?
Amino Acid Sequence
D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Side Effects & Safety
- Cortisol and ACTH elevation
- Appetite stimulation
- Water retention
- Flushing or warmth sensation
- Fatigue
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Uncontrolled Diabetes Mellitus
Severe Cardiac Disease
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Drug Interactions
- Insulin / Oral Hypoglycemics:
FDA Safety Information
FDA Category 2 concerns: immunogenicity, unnatural amino acid, reports of increased insulin requirement, death, infection, pancreatitis.
Pharmacokinetics
| Half-Life | ~15-60 minutes |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside GHRP-2 for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.